Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Procrit Early vs Standard Intervention in Cancer Anemia
NCT00255749Phase 2Completed
- Sponsor
- UCLA Jonsson Comprehensive Cancer Center
- Start
- Aug 2005
- Primary completion
- Apr 2007
- Modality
- Biologic, rProtein (Recombinant Protein)
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of epoetin alfa in anemia (2 arms), sponsored by UCLA Jonsson Comprehensive Cancer Center. Primary endpoints: Efficacy (maintenance of target hemoglobin and hematocrit levels) at 7 weeks and Safety at 7 weeks. Started Aug 2005; status: completed.
02
Drugs
epoetin alfa
03
Conditions
anemia
Beyond the preview
Go deeper on NCT00255749.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00255749.